Trials / Completed
CompletedNCT00324194
A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes
A Phase I Study of MGCD0103 Given as a Twice Weekly Oral Dose in Patients With Leukemia or Myelodysplastic Syndromes
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Mirati Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study, MGCD0103, a new anticancer drug under investigation, is given twice weekly to patients with leukemia or myelodysplastic syndromes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MGCD0103 | MGCD0103 oral dose given 2 times per week. |
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2008-03-01
- Completion
- 2008-08-01
- First posted
- 2006-05-10
- Last updated
- 2015-01-08
Locations
4 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00324194. Inclusion in this directory is not an endorsement.